These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 25834802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [Abstract] [Full Text] [Related]

  • 5. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 6. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 7. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 8. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 06; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 9. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
    Chang AY, Wang M.
    Anticancer Drugs; 2013 Mar 06; 24(3):251-9. PubMed ID: 23187461
    [Abstract] [Full Text] [Related]

  • 10. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun 06; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

  • 11. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.
    J Hepatol; 2012 Jul 14; 57(1):108-15. PubMed ID: 22414764
    [Abstract] [Full Text] [Related]

  • 13. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
    Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P.
    J Pineal Res; 2017 Apr 14; 62(3):. PubMed ID: 28178378
    [Abstract] [Full Text] [Related]

  • 14. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 14; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 15. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC.
    Anticancer Res; 2018 Apr 14; 38(4):2119-2125. PubMed ID: 29599330
    [Abstract] [Full Text] [Related]

  • 16. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 14; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 17. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 May 14; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 18. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 14; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 19. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM.
    J Surg Res; 2013 Nov 14; 185(1):225-30. PubMed ID: 23769634
    [Abstract] [Full Text] [Related]

  • 20. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L.
    PLoS One; 2015 Nov 14; 10(9):e0138485. PubMed ID: 26381511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.